ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01908621
Recruitment Status : Unknown
Verified July 2013 by Maria Sklodowska-Curie Institute - Oncology Center.
Recruitment status was:  Recruiting
First Posted : July 25, 2013
Last Update Posted : July 25, 2013
Sponsor:
Information provided by (Responsible Party):
Maria Sklodowska-Curie Institute - Oncology Center

Brief Summary:
The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in multiple myeloma patients.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: G-CSF (filgrastim) Drug: Cytosine arabinoside + G-CSF (filgrastim) Phase 3

Detailed Description:

Autologous hematopoietic stem cell transplantation (autoHSCT) is a standard treatment of eligible patients suffering from multiple myeloma (MM). Tandem autoHSCT allows to further improve results of the therapy. Nowadays, 99% of the procedures are performed using peripheral blood as a source of stem cells. Hence, the crucial point is to harvest adequate number of stem cells allowing hematopoietic recovery. The number of 5 × 10^6 CD34+ cells/kg is considered the optimal level, as far as double autoHSCT is concerned. There are two main mobilization strategies being used: based on G-CSF alone or in combination with chemotherapy (cyclophosphamide (CY) at dose range 1.5-7 g/m2 is mainly used in MM setting). However, a proportion of patients (5-40%) fail to collect the minimum number of cells required. Novel agents, like plerixafor, CXCR4 inhibitor, may enable effective CD34+ cell harvest in "poor mobilizers". Nevertheless, the optimal first-line and cost-effective protocol for mobilization of hematopoietic stem cells has not been determined so far.

Randomized trials comparing chemomobilization with use of CY + G-CSF to G-CSF alone, which had been conducted so far, did not demonstrate clear advantage of addition of CY to growth factor. Intermediate-dose cytosine arabinoside (AraC), 1.6 g/m2 plus filgrastim, has been shown to produce very high efficacy as a first or second-line mobilization regimen in patients with lymphoid malignancies, including MM. In a retrospective comparison, this strategy was significantly more effective than CY + filgrastim. This suggest that the type of chemotherapy agent added to G-CSF may play role in mobilization efficacy and that the combination of AraC and G-CSF may be more effective than G-CSF used alone. The goal of current study is to verify this hypothesis in randomized controlled trial.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Multiple Myeloma Patients.
Study Start Date : March 2013
Estimated Primary Completion Date : December 2013


Arm Intervention/treatment
Active Comparator: G-CSF (filgrastim)
Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
Drug: G-CSF (filgrastim)
Active Comparator: Cytosine arabinoside + G-CSF (filgrastim)
Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
Drug: Cytosine arabinoside + G-CSF (filgrastim)



Primary Outcome Measures :
  1. The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm. [ Time Frame: After up to three leukaphereses (7-20 days after starting mobilization regimen). ]

Secondary Outcome Measures :
  1. Peak level of CD34+ cells in peripheral blood (/μl). [ Time Frame: 7-20 days after starting mobilization regimen. ]
  2. Total number of harvested CD34+cells/kg. [ Time Frame: Ater up to three leukaphereses (7-20 days after starting mobilization regimen). ]
  3. Number of leukaphereses needed to harvest target amount of stem cells. [ Time Frame: 7-20 days after starting mobilization regimen. ]
  4. The proportion of hematologic and non-hematologic complications. [ Time Frame: 1 month ]
  5. Duration of neutropenia < 0.5 x10^9/L and thrombocytopenia <50 x10^9/L. [ Time Frame: 1 month ]
  6. Number of blood transfusions needed and number of days of antibiotics therapy. [ Time Frame: 1 month ]
  7. Duration of hospital stay. [ Time Frame: 1 month ]
  8. Time of neutrophil and platelet engraftment after autologous stem cel transplantation. [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Multiple myeloma patients considered eligible for tandem autologous stm cell transplantation procedure.
  2. Must have received at least one line of therapy including six or more cycles containing components like thalidomide, bortezomib, lenalidomide or melphalan.
  3. Must have achieved a partial remission (PR) or better response as assessed by International Myeloma Working Group guidelines.
  4. Must be 18-65 years of age.
  5. Must have World Health Organization performance status 0-1.
  6. Time form discontinuation of administration of any chemotherapy agent must be at least four weeks and immunomodulatory drug at least seven days.
  7. Hemoglobin level > 8 g/dl, Absolute neutrophil count (ANC) > 1.5 x 109/L, Platelet count >100 x 109/L.
  8. Serum creatinine < 1.5 x upper limit of normal (ULN), serum bilirubin < 1.5 ULN, serum aspartate transaminase (AST/SGOT) < 2.5 x ULN, serum alanine transaminase (ALT/SGPT) < 2.5 x ULN.
  9. Negative human immunodeficiency virus (HIV) infection test.
  10. Negative pregnancy test.
  11. Must understand and voluntarily sign informed consent form.

Exclusion Criteria:

  1. Failure of prior, first-line mobilization regimen.
  2. Bone marrow plasma cell infiltration of above 20%.
  3. Administration of growth-factor other than G-CSF within 4 weeks before starting study treatment.
  4. Administration of G-CSF within 14 days before starting study treatment.
  5. Ongoing or active infection.
  6. Coexisting neoplasm, other than multiple myeloma.
  7. Pregnant or lactating females.
  8. Patients treated with use of autologous or allogenic stem cell transplantation in the past.
  9. Positive human immunodeficiency virus (HIV) infection test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01908621


Contacts
Contact: Tomasz Czerw, MD +48322788523 tomcmed@gmail.com

Locations
Poland
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch Recruiting
Gliwice, Poland, 44-101
Contact: Sebastian Giebel, Assoc. prof.    +48322788523    ots@gliwice.io.pl   
Principal Investigator: Tomasz Czerw, MD         
Sponsors and Collaborators
Maria Sklodowska-Curie Institute - Oncology Center

Publications:

Responsible Party: Maria Sklodowska-Curie Institute - Oncology Center
ClinicalTrials.gov Identifier: NCT01908621     History of Changes
Other Study ID Numbers: MMMobil-COI-01
First Posted: July 25, 2013    Key Record Dates
Last Update Posted: July 25, 2013
Last Verified: July 2013

Keywords provided by Maria Sklodowska-Curie Institute - Oncology Center:
multiple myeloma
mobilization
G-CSF
filgrastim
cytosine arabinoside
autologous stem cell transplantation

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lenograstim
Cytarabine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents